78例小细胞肺癌患者脑转移发生时间的相关因素初步研究-现代医学

78例小细胞肺癌患者脑转移发生时间的相关因素初步研究

单位：中国医科大学附属盛京医院第四肿瘤科, 辽宁沈阳 110020

分类号：R734.2

出版年·卷·期（页码）：2017·36·第十一期（1642-1645）

摘要：

目的：对小细胞肺癌患者发生脑转移时间的影响因素进行分析。方法：统计78例发生脑转移的小细胞肺癌患者的临床资料，采用住院观察和电话形式进行随访，应用卡方检验进行单因素分析，行Logistic多因素分析，得出独立危险因素。结果：单因素分析显示，患者发生脑转移的时间与确诊时分期（χ²=7.657，P=0.006）、确诊时血清NSE水平（χ²=5.200，P=0.023）、是否行预防性全脑照射（PCI）治疗（χ²=5.200，P=0.023）和是否行手术切除治疗（χ²=3.989，P=0.046）有关。多因素分析显示，广泛期和未行PCI治疗是小细胞肺癌较早发生脑转移的独立危险因素。结论：广泛期和未行PCI治疗的小细胞肺癌患者更易较早发生脑转移，采用PCI治疗后可延迟发生脑转移的时间。对小细胞肺癌患者病灶及症状得到控制后，应尽早行PCI治疗。

Objective:To evaluate influencing factors on the time that patients ocurre brain metastasis in small cell lung cancer. Methods:Clinical data of 78 patients with brain metastasis in small cell lung cancer were collected, followed up by telephone interview and hospitalization observation. Using Chi-squareunivariate analysis was conducted to obtain the independent risk factors by the multivariate logistic analysis. Results:Single factor analysis showed that the time of brain metastasis in small cell lung cancer patients was related with diagnosis staging(χ²=7.657,P=0.006), the level of serum NSE in diagnosis(χ²=5.200,P=0.023), PCI treatment(χ²=5.200,P=0.023)and surgery(χ²=3.989,P=0.046). The multivariate analysis concluded that ED-SCLC and without PCI were the independent risk factors for early brain metastasis in small cell lung cancer. Conclusion:The patients who were ED-SCLC or treated without PCI were more likely to occur early brain metastasis. However, patients treated with PCI can delay the time of brain metastasis. When patients are in stable situation, we should reco mmend tailored PCI as soon as possible

参考文献：

[1] SEUTE T,LEFFERS P,WILMINK J T,et al.Response of asymptomatic brain metastases from small-cell lung cancer to systemic first-line chemotherapy[J].J Clin Oncol,2006,24(13):2079-2083.
[2] RODRIGUEZ E,LILENBAUM R C.Small cell lung cancer:past,present,and future[J].Curr Oncol Rep,2010,12(5):327-334.
[3] KALEMKERIAN G P,AKERLEY W,BOGNER P,et al.Small cell lung cancer[J],J Natl Compr Canc Netw,2013,11(1):78-98.
[4] STAMATIS G.Neuroendocrine tumors of the lung:the role of surgery in small cell lung cancer[J].Thorac Surg Clin,2014,24(3):313-326.
[5] van MEERBEECK J P,FENNELL D A,de RUYSSCHER D K.Small-cell lung cancer[J].Lancet,2011,378(9804):1741-1755.
[6] PATEL S,MACDONALD O K,SUNTHARALINGAM M.Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer[J].Cancer,2009,115(4):842-850.
[7] KUO Y H,LIN Z Z,YANG Y Y,et al.Survival of patients with small cell lung carcinoma in Taiwan[J].Oncology,2012,82(1):19-24.
[8] OLSON A C,WEGNER R E,RWIGEMA J C,et al.Clinical outcomes of reirradiation of brain metastases from small cell lung cancer with cyberknife stereotactic radiosurgery[J].J Cancer Res Ther,2012,8(3):411-416.
[9] NAKAZAKI K,HIGUCHI Y,NAGANO O,et al.Efficacy and limitations of salvage ga mma knife radiosurgery for brain metastases of small-cell lung cancer after whole-brain radiotherapy[J].Acta Neurochir (Wien),2013,155(1):107-113.
[10] le PECHOUX C,DUNANT A,SENAN S,et al.Standard-dose versus higher-dose prophylactic cranial irradiation(PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy(PCI 99-01,EORTC 22003-08004,RTOG 0212,and IFCT 99-01):a randomized clinical trial[J].Lancet Oncol,2009,10(5):467-474.
[11] SORENSEN M,PIJLS-JOHANNESMA M,FELIP E.ESMO Clinical practice guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2010,21(5):120-125.
[12] PLOENES T,OSEI-AGYEMANG T,KROHN A,et al.Surgical treatment of early stage small cell lung cancer[J].Asian Cardiovasc Thorac Ann,2012,20(6):694-698.
[13] SCHILD S E,FOSTER N R,MEYERS J P,et al.Prophylactic cranial irradiation in small cell lung cancer:findings from a north central cancer treatment group pooled analysis[J].Ann Oncol,2012,23(11):2919-2924.
[14] JOHNSON B E,JANNE P A.Basic treatment considerations using chemotherapy for patients with small cell lung cancer[J].Hematol Oncol Clin North Am,2004,18(2):309-322.
[15] WOLFSON A H,BAE K,KOMAKI R,et al,Primary analysis of a phase Ⅱ randomized trial radiation therapy oncology group(RTOG) 0212:impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited -disease small -cell lung cancer[J].Int J Radiat Oncol Biol Phys,2011,81(1):77-84.
[16] 钟润波,韩宝惠,白皓,等.98例广泛期小细胞肺癌预后多因素分析[J].临床肿瘤学杂志,2010,15(9):802-806.
[17] AUPERIN A,ARRIAGADA R,PIGNON J P,et al.Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission.Prophylactic Cranial Irradiation Overview Collaborative Group[J].N Engl J Med,1999,341(7):476-484.
[18] HARMSMA M,SCHUTTE B,RAMAEKERS F C.Serum markers in smallcell lung cancer:opportunities for improvement[J].Biochim Biophys Acta,2013,1836(2):255-272.
[19] ZHAO W X,LUO J F.Serum neuron-specific enolase levels were associated with the prognosis of small cell lung cancer:a meta-analysis[J].Tumour Biol,2013,34(5):3245-3248.
[20] 黄春月,陈文霞,朱伟良,等.小细胞肺癌分子标记物研究进展[J].现代生物医学进展,2014,14(33):6589-6596.
[21] ZHANG W W,JIANG W J,LUAN L L,et al.Prophylactic cranial irradiation for patients with small-cell lung cancer:a systematic review of the literature with meta-analysis[J].BMC Cancer,2014,14(1):793-799.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录